Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing
The authors describe the operational requirements and design of a process-ready PAT-based IBD system.


Pharmaceutical Technology
Volume 34, pp. s18-s22

Chromatography is an integral step in downstream bioprocessing, and buffered mobile-phase properties such as ionic strength and pH are often critical process parameters for protein purification. The interactions between the mobile and stationary phases can affect chromatographic performance, and thus the separation profile between product and impurities. Product recovery, purity, and throughput are often marred by the variability in buffer preparation during production-scale bioprocessing. The popular approach to biological production typically relies on postchromatographic adjustments (e.g., fractionation controlled by ultraviolet (UV) signal and segregation of out-of-specification product through quality-control testing) to achieve the desired product quality. Although the US Food and Drug Administration accepts this traditional practice, this post-process approach to quality control is time-consuming, increases production cost, and does not provide the process understanding and control from the quality-by-design (QbD) approach that FDA promotes.

Process analytical technology

In accordance with FDA's Pharmaceutical CGMPs for the 21st Century initiatives, companies should employ process monitoring and control strategies to streamline biopharmaceutical manufacturing. Real-time process knowledge can help manufacturers avoid excessive rework and discarded product. To achieve this standard of quality, FDA highly recommends the implementation of process analytical technology (PAT) to facilitate a QbD approach. According to FDA, the working definition of PAT is "a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during process) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality" (1).

Many modern technniques for process analysis such as pH measurement, near-infrared spectroscopy, Raman spectroscopy, refractive-index changes, humidity movement, UV monitoring, conductivity detection, and dissolved-oxygen analysis are commercially available for different applications. These analytical tools can measure physical and chemical properties of raw materials directly in real time, in contrast with techniques such as flow-meter monitoring, which only makes indirect measurements.

Applications of PAT in downstream bioprocessing


Figure 1: Conventional system for buffer preparation and delivery. CGMP is current good manufacturing practices, CIP is clean-in-place, and QC is quality control. (ALL IMAGES ARE COURTESY OF THE AUTHORS)
In the past 10 years, protein-expression titers have increased 1000 times from mg/L to g/L. As upstream yields continue to increase, downstream bioprocessing involving buffer preparations and delivery also must increase proportionally to keep pace with demand. Therefore, conventional practices of preparing and delivering buffers have to be modified or replaced with new manufacturing sciences (see Figure 1). This principle is especially true for industrial-scale quantities of buffers that must be reproducibile and meet tight specifications. Scientists at Genentech (South San Francisco, CA) proposed using mass-flow meters to dilute buffers from concentrates, which is a great improvement (2). The scientists described the dilution of concentrated acetone, which could be monitored by an in-line optical-density meter. Additional monitoring through feedback control of conductivity and pH can complement the design and reduce the variability of buffer feedstock, preparation, and delivery frequently encountered in bioprocessing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here